A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
NCT07584967
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Heart Failure With Reduced Ejection Fraction (HFrEF)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AnaCardio AB
- Last updated on ClinicalTrials.gov
- November 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Progressive MD, InvivoCure · Van Nuys, CA
Florida · 1
- Nature Coast Clinical Research · Crystal River, FL
Illinois · 1
- Chicago Cardiology Institute · Schaumburg, IL
Pennsylvania · 1
- Capital Area Research, LLC - Camp Hill · Camp Hill, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.